Ferumoxytol is an ultrasmall superparamagnetic iron oxide agent marketed for the treatment of anemia. There has been increasing interest in its properties as an MRI contrast agent as well as greater awareness of its adverse event profile. This mini‐review summarizes the current state of knowledge of the risks of ferumoxytol and methods of administration. Magn Reson Med 75:2107–2111, 2016.

Multicenter off-label experience in 4240 diagnostic ferumoxytol injections for MRI at nine sites in the United States and two sites in the United Kingdom showed no serious adverse events or adverse... Background Ferumoxytol is approved for use in the treatment of iron deficiency anemia, but it can serve as an alternative to gadolinium-based contrast agents. On the basis of postmarketing surveill...

The field of tissue engineering continues to advance, sometimes in exponential leaps forward, but also sometimes at a rate that does not fulfill the promise that the field imagined a few decades ago. This review is in part a catalog of success in an effort to inform the process of innovation. Tissue engineering has recruited new technologies and developed new methods for engineering tissue constructs that can be used to mitigate or model disease states for study. Key to this antecedent statement is that the scientific effort must be anchored in the needs of a disease state and be working toward a functional product in regenerative medicine. It is this focus on the wildly important ideas coupled with partnered research efforts within both academia and industry that have shown most translational potential. The field continues to thrive and among the most important recent developments are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies that warrant special attention. Developments in the aforementioned areas as well as future directions are highlighted in this article. Although several early efforts have not come to fruition, there are good examples of commercial profitability that merit continued investment in tissue engineering. Impact statement: Tissue engineering led to the development of new methods for regenerative medicine and disease models. Among the most important recent developments in tissue engineering are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies. These technologies and an understanding of them will have impact on the success of tissue engineering and its translation to regenerative medicine. Continued investment in tissue engineering will yield products and therapeutics, with both commercial importance and simultaneous disease mitigation.

Background: To review and evaluate approaches to convolutional neural network (CNN) reconstruction for accelerated cardiac MR imaging in the real clinical context. Methods: Two CNN architectures, Unet and residual network (Resnet) were evaluated using quantitative and qualitative assessment by radiologist. Four different loss functions were also considered: pixel-wise (L1 and L2), patch-wise structural dissimilarity (Dssim) and feature-wise (perceptual loss). The networks were evaluated using retrospectively and prospectively under-sampled cardiac MR data. Results: Based on our assessments, we find that Resnet and Unet achieve similar image quality but that former requires only 100,000 parameters compared to 1.3 million parameters for the latter. The perceptual loss function performed significantly better than L1, L2 or Dssim loss functions as determined by the radiologist scores. Conclusions: CNN image reconstruction using Resnet yields comparable image quality to Unet with 10X the number of parameters. This has implications for training with significantly lower data requirements. Network training using the perceptual loss function was found to better agree with radiologist scoring compared to L1, L2 or Dssim loss functions.